Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:

★Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

★Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

★Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

★Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

1 Study Coverage
1.1 Introduction to Full-Service CDMO: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Full-Service CDMO Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 API CDMO
1.2.3 FDF CDMO
1.2.4 Packaging CDMO
1.2.5 Clinical CDMO
1.3 Market Segmentation by Application
1.3.1 Global Full-Service CDMO Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Full-Service CDMO Revenue Estimates and Forecasts 2020-2031
2.2 Global Full-Service CDMO Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Full-Service CDMO Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Full-Service CDMO Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 API CDMO Market Size by Players
3.3.2 FDF CDMO Market Size by Players
3.3.3 Packaging CDMO Market Size by Players
3.3.4 Clinical CDMO Market Size by Players
3.4 Global Full-Service CDMO Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Full-Service CDMO Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Full-Service CDMO Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Full-Service CDMO Market Size by Type (2020-2031)
6.4 North America Full-Service CDMO Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Full-Service CDMO Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Full-Service CDMO Market Size by Type (2020-2031)
7.4 Europe Full-Service CDMO Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Full-Service CDMO Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Full-Service CDMO Market Size by Type (2020-2031)
8.4 Asia-Pacific Full-Service CDMO Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Full-Service CDMO Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Full-Service CDMO Market Size by Type (2020-2031)
9.4 Central and South America Full-Service CDMO Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Full-Service CDMO Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Full-Service CDMO Market Size by Type (2020-2031)
10.4 Middle East and Africa Full-Service CDMO Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Full-Service CDMO Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Lonza
11.1.1 Lonza Corporation Information
11.1.2 Lonza Business Overview
11.1.3 Lonza Full-Service CDMO Product Features and Attributes
11.1.4 Lonza Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.1.5 Lonza Full-Service CDMO Revenue by Product in 2024
11.1.6 Lonza Full-Service CDMO Revenue by Application in 2024
11.1.7 Lonza Full-Service CDMO Revenue by Geographic Area in 2024
11.1.8 Lonza Full-Service CDMO SWOT Analysis
11.1.9 Lonza Recent Developments
11.2 Catalent
11.2.1 Catalent Corporation Information
11.2.2 Catalent Business Overview
11.2.3 Catalent Full-Service CDMO Product Features and Attributes
11.2.4 Catalent Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.2.5 Catalent Full-Service CDMO Revenue by Product in 2024
11.2.6 Catalent Full-Service CDMO Revenue by Application in 2024
11.2.7 Catalent Full-Service CDMO Revenue by Geographic Area in 2024
11.2.8 Catalent Full-Service CDMO SWOT Analysis
11.2.9 Catalent Recent Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Corporation Information
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Full-Service CDMO Product Features and Attributes
11.3.4 Thermo Fisher Scientific Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.3.5 Thermo Fisher Scientific Full-Service CDMO Revenue by Product in 2024
11.3.6 Thermo Fisher Scientific Full-Service CDMO Revenue by Application in 2024
11.3.7 Thermo Fisher Scientific Full-Service CDMO Revenue by Geographic Area in 2024
11.3.8 Thermo Fisher Scientific Full-Service CDMO SWOT Analysis
11.3.9 Thermo Fisher Scientific Recent Developments
11.4 Samsung Biologics
11.4.1 Samsung Biologics Corporation Information
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Full-Service CDMO Product Features and Attributes
11.4.4 Samsung Biologics Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.4.5 Samsung Biologics Full-Service CDMO Revenue by Product in 2024
11.4.6 Samsung Biologics Full-Service CDMO Revenue by Application in 2024
11.4.7 Samsung Biologics Full-Service CDMO Revenue by Geographic Area in 2024
11.4.8 Samsung Biologics Full-Service CDMO SWOT Analysis
11.4.9 Samsung Biologics Recent Developments
11.5 Fareva
11.5.1 Fareva Corporation Information
11.5.2 Fareva Business Overview
11.5.3 Fareva Full-Service CDMO Product Features and Attributes
11.5.4 Fareva Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.5.5 Fareva Full-Service CDMO Revenue by Product in 2024
11.5.6 Fareva Full-Service CDMO Revenue by Application in 2024
11.5.7 Fareva Full-Service CDMO Revenue by Geographic Area in 2024
11.5.8 Fareva Full-Service CDMO SWOT Analysis
11.5.9 Fareva Recent Developments
11.6 WuXi AppTech
11.6.1 WuXi AppTech Corporation Information
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Full-Service CDMO Product Features and Attributes
11.6.4 WuXi AppTech Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.6.5 WuXi AppTech Recent Developments
11.7 WuXi Biologics
11.7.1 WuXi Biologics Corporation Information
11.7.2 WuXi Biologics Business Overview
11.7.3 WuXi Biologics Full-Service CDMO Product Features and Attributes
11.7.4 WuXi Biologics Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.7.5 WuXi Biologics Recent Developments
11.8 Siegfried
11.8.1 Siegfried Corporation Information
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Full-Service CDMO Product Features and Attributes
11.8.4 Siegfried Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.8.5 Siegfried Recent Developments
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Full-Service CDMO Product Features and Attributes
11.9.4 FUJIFILM Diosynth Biotechnologies Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
11.10 Asymchem
11.10.1 Asymchem Corporation Information
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Full-Service CDMO Product Features and Attributes
11.10.4 Asymchem Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Corporation Information
11.11.2 Pfizer CentreOne Business Overview
11.11.3 Pfizer CentreOne Full-Service CDMO Product Features and Attributes
11.11.4 Pfizer CentreOne Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.11.5 Pfizer CentreOne Recent Developments
11.12 Delpharm
11.12.1 Delpharm Corporation Information
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Full-Service CDMO Product Features and Attributes
11.12.4 Delpharm Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.12.5 Delpharm Recent Developments
11.13 Recipharm
11.13.1 Recipharm Corporation Information
11.13.2 Recipharm Business Overview
11.13.3 Recipharm Full-Service CDMO Product Features and Attributes
11.13.4 Recipharm Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.13.5 Recipharm Recent Developments
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Corporation Information
11.14.2 AGC Pharma Chemicals Business Overview
11.14.3 AGC Pharma Chemicals Full-Service CDMO Product Features and Attributes
11.14.4 AGC Pharma Chemicals Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.14.5 AGC Pharma Chemicals Recent Developments
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Corporation Information
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Full-Service CDMO Product Features and Attributes
11.15.4 Boehringer Ingelheim Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.15.5 Boehringer Ingelheim Recent Developments
11.16 Vetter
11.16.1 Vetter Corporation Information
11.16.2 Vetter Business Overview
11.16.3 Vetter Full-Service CDMO Product Features and Attributes
11.16.4 Vetter Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.16.5 Vetter Recent Developments
11.17 Curia
11.17.1 Curia Corporation Information
11.17.2 Curia Business Overview
11.17.3 Curia Full-Service CDMO Product Features and Attributes
11.17.4 Curia Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.17.5 Curia Recent Developments
11.18 Aenova
11.18.1 Aenova Corporation Information
11.18.2 Aenova Business Overview
11.18.3 Aenova Full-Service CDMO Product Features and Attributes
11.18.4 Aenova Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.18.5 Aenova Recent Developments
11.19 Porton
11.19.1 Porton Corporation Information
11.19.2 Porton Business Overview
11.19.3 Porton Full-Service CDMO Product Features and Attributes
11.19.4 Porton Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.19.5 Porton Recent Developments
11.20 Piramal
11.20.1 Piramal Corporation Information
11.20.2 Piramal Business Overview
11.20.3 Piramal Full-Service CDMO Product Features and Attributes
11.20.4 Piramal Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.20.5 Piramal Recent Developments
11.21 Strides Pharma
11.21.1 Strides Pharma Corporation Information
11.21.2 Strides Pharma Business Overview
11.21.3 Strides Pharma Full-Service CDMO Product Features and Attributes
11.21.4 Strides Pharma Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.21.5 Strides Pharma Recent Developments
11.22 NextPharma
11.22.1 NextPharma Corporation Information
11.22.2 NextPharma Business Overview
11.22.3 NextPharma Full-Service CDMO Product Features and Attributes
11.22.4 NextPharma Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.22.5 NextPharma Recent Developments
11.23 Famar
11.23.1 Famar Corporation Information
11.23.2 Famar Business Overview
11.23.3 Famar Full-Service CDMO Product Features and Attributes
11.23.4 Famar Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.23.5 Famar Recent Developments
11.24 Jubilant
11.24.1 Jubilant Corporation Information
11.24.2 Jubilant Business Overview
11.24.3 Jubilant Full-Service CDMO Product Features and Attributes
11.24.4 Jubilant Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.24.5 Jubilant Recent Developments
11.25 Alcami
11.25.1 Alcami Corporation Information
11.25.2 Alcami Business Overview
11.25.3 Alcami Full-Service CDMO Product Features and Attributes
11.25.4 Alcami Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.25.5 Alcami Recent Developments
11.26 Euroapi
11.26.1 Euroapi Corporation Information
11.26.2 Euroapi Business Overview
11.26.3 Euroapi Full-Service CDMO Product Features and Attributes
11.26.4 Euroapi Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.26.5 Euroapi Recent Developments
11.27 Eurofins
11.27.1 Eurofins Corporation Information
11.27.2 Eurofins Business Overview
11.27.3 Eurofins Full-Service CDMO Product Features and Attributes
11.27.4 Eurofins Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.27.5 Eurofins Recent Developments
11.28 Avid Bioservices
11.28.1 Avid Bioservices Corporation Information
11.28.2 Avid Bioservices Business Overview
11.28.3 Avid Bioservices Full-Service CDMO Product Features and Attributes
11.28.4 Avid Bioservices Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.28.5 Avid Bioservices Recent Developments
11.29 BioVectra
11.29.1 BioVectra Corporation Information
11.29.2 BioVectra Business Overview
11.29.3 BioVectra Full-Service CDMO Product Features and Attributes
11.29.4 BioVectra Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.29.5 BioVectra Recent Developments
11.30 CPL
11.30.1 CPL Corporation Information
11.30.2 CPL Business Overview
11.30.3 CPL Full-Service CDMO Product Features and Attributes
11.30.4 CPL Full-Service CDMO Revenue and Gross Margin (2020-2025)
11.30.5 CPL Recent Developments
12 Full-Service CDMOIndustry Chain Analysis
12.1 Full-Service CDMO Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Full-Service CDMO Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Full-Service CDMO Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Full-Service CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Full-Service CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Full-Service CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Full-Service CDMO Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Full-Service CDMO Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Full-Service CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Full-Service CDMO Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Full-Service CDMO by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Full-Service CDMO as of 2024)
Table 11. Global Full-Service CDMO Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Full-Service CDMO Companies Headquarters
Table 13. Global Full-Service CDMO Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Full-Service CDMO Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Full-Service CDMO Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Full-Service CDMO Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Full-Service CDMO Revenue by Application (2026-2031) & (US$ Million)
Table 21. Full-Service CDMO High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Full-Service CDMO Growth Accelerators and Market Barriers
Table 25. North America Full-Service CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Full-Service CDMO Growth Accelerators and Market Barriers
Table 27. Europe Full-Service CDMO Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Full-Service CDMO Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Full-Service CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Full-Service CDMO Investment Opportunities and Key Challenges
Table 31. Central and South America Full-Service CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Full-Service CDMO Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Full-Service CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Lonza Corporation Information
Table 35. Lonza Description and Major Businesses
Table 36. Lonza Product Features and Attributes
Table 37. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Lonza Revenue Proportion by Product in 2024
Table 39. Lonza Revenue Proportion by Application in 2024
Table 40. Lonza Revenue Proportion by Geographic Area in 2024
Table 41. Lonza Full-Service CDMO SWOT Analysis
Table 42. Lonza Recent Developments
Table 43. Catalent Corporation Information
Table 44. Catalent Description and Major Businesses
Table 45. Catalent Product Features and Attributes
Table 46. Catalent Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Catalent Revenue Proportion by Product in 2024
Table 48. Catalent Revenue Proportion by Application in 2024
Table 49. Catalent Revenue Proportion by Geographic Area in 2024
Table 50. Catalent Full-Service CDMO SWOT Analysis
Table 51. Catalent Recent Developments
Table 52. Thermo Fisher Scientific Corporation Information
Table 53. Thermo Fisher Scientific Description and Major Businesses
Table 54. Thermo Fisher Scientific Product Features and Attributes
Table 55. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 57. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 58. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 59. Thermo Fisher Scientific Full-Service CDMO SWOT Analysis
Table 60. Thermo Fisher Scientific Recent Developments
Table 61. Samsung Biologics Corporation Information
Table 62. Samsung Biologics Description and Major Businesses
Table 63. Samsung Biologics Product Features and Attributes
Table 64. Samsung Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Samsung Biologics Revenue Proportion by Product in 2024
Table 66. Samsung Biologics Revenue Proportion by Application in 2024
Table 67. Samsung Biologics Revenue Proportion by Geographic Area in 2024
Table 68. Samsung Biologics Full-Service CDMO SWOT Analysis
Table 69. Samsung Biologics Recent Developments
Table 70. Fareva Corporation Information
Table 71. Fareva Description and Major Businesses
Table 72. Fareva Product Features and Attributes
Table 73. Fareva Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Fareva Revenue Proportion by Product in 2024
Table 75. Fareva Revenue Proportion by Application in 2024
Table 76. Fareva Revenue Proportion by Geographic Area in 2024
Table 77. Fareva Full-Service CDMO SWOT Analysis
Table 78. Fareva Recent Developments
Table 79. WuXi AppTech Corporation Information
Table 80. WuXi AppTech Description and Major Businesses
Table 81. WuXi AppTech Product Features and Attributes
Table 82. WuXi AppTech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. WuXi AppTech Recent Developments
Table 84. WuXi Biologics Corporation Information
Table 85. WuXi Biologics Description and Major Businesses
Table 86. WuXi Biologics Product Features and Attributes
Table 87. WuXi Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. WuXi Biologics Recent Developments
Table 89. Siegfried Corporation Information
Table 90. Siegfried Description and Major Businesses
Table 91. Siegfried Product Features and Attributes
Table 92. Siegfried Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Siegfried Recent Developments
Table 94. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 95. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
Table 96. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
Table 97. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 99. Asymchem Corporation Information
Table 100. Asymchem Description and Major Businesses
Table 101. Asymchem Product Features and Attributes
Table 102. Asymchem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Asymchem Recent Developments
Table 104. Pfizer CentreOne Corporation Information
Table 105. Pfizer CentreOne Description and Major Businesses
Table 106. Pfizer CentreOne Product Features and Attributes
Table 107. Pfizer CentreOne Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Pfizer CentreOne Recent Developments
Table 109. Delpharm Corporation Information
Table 110. Delpharm Description and Major Businesses
Table 111. Delpharm Product Features and Attributes
Table 112. Delpharm Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Delpharm Recent Developments
Table 114. Recipharm Corporation Information
Table 115. Recipharm Description and Major Businesses
Table 116. Recipharm Product Features and Attributes
Table 117. Recipharm Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Recipharm Recent Developments
Table 119. AGC Pharma Chemicals Corporation Information
Table 120. AGC Pharma Chemicals Description and Major Businesses
Table 121. AGC Pharma Chemicals Product Features and Attributes
Table 122. AGC Pharma Chemicals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. AGC Pharma Chemicals Recent Developments
Table 124. Boehringer Ingelheim Corporation Information
Table 125. Boehringer Ingelheim Description and Major Businesses
Table 126. Boehringer Ingelheim Product Features and Attributes
Table 127. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Boehringer Ingelheim Recent Developments
Table 129. Vetter Corporation Information
Table 130. Vetter Description and Major Businesses
Table 131. Vetter Product Features and Attributes
Table 132. Vetter Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Vetter Recent Developments
Table 134. Curia Corporation Information
Table 135. Curia Description and Major Businesses
Table 136. Curia Product Features and Attributes
Table 137. Curia Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Curia Recent Developments
Table 139. Aenova Corporation Information
Table 140. Aenova Description and Major Businesses
Table 141. Aenova Product Features and Attributes
Table 142. Aenova Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Aenova Recent Developments
Table 144. Porton Corporation Information
Table 145. Porton Description and Major Businesses
Table 146. Porton Product Features and Attributes
Table 147. Porton Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Porton Recent Developments
Table 149. Piramal Corporation Information
Table 150. Piramal Description and Major Businesses
Table 151. Piramal Product Features and Attributes
Table 152. Piramal Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Piramal Recent Developments
Table 154. Strides Pharma Corporation Information
Table 155. Strides Pharma Description and Major Businesses
Table 156. Strides Pharma Product Features and Attributes
Table 157. Strides Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 158. Strides Pharma Recent Developments
Table 159. NextPharma Corporation Information
Table 160. NextPharma Description and Major Businesses
Table 161. NextPharma Product Features and Attributes
Table 162. NextPharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 163. NextPharma Recent Developments
Table 164. Famar Corporation Information
Table 165. Famar Description and Major Businesses
Table 166. Famar Product Features and Attributes
Table 167. Famar Revenue (US$ Million) and Gross Margin (2020-2025)
Table 168. Famar Recent Developments
Table 169. Jubilant Corporation Information
Table 170. Jubilant Description and Major Businesses
Table 171. Jubilant Product Features and Attributes
Table 172. Jubilant Revenue (US$ Million) and Gross Margin (2020-2025)
Table 173. Jubilant Recent Developments
Table 174. Alcami Corporation Information
Table 175. Alcami Description and Major Businesses
Table 176. Alcami Product Features and Attributes
Table 177. Alcami Revenue (US$ Million) and Gross Margin (2020-2025)
Table 178. Alcami Recent Developments
Table 179. Euroapi Corporation Information
Table 180. Euroapi Description and Major Businesses
Table 181. Euroapi Product Features and Attributes
Table 182. Euroapi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 183. Euroapi Recent Developments
Table 184. Eurofins Corporation Information
Table 185. Eurofins Description and Major Businesses
Table 186. Eurofins Product Features and Attributes
Table 187. Eurofins Revenue (US$ Million) and Gross Margin (2020-2025)
Table 188. Eurofins Recent Developments
Table 189. Avid Bioservices Corporation Information
Table 190. Avid Bioservices Description and Major Businesses
Table 191. Avid Bioservices Product Features and Attributes
Table 192. Avid Bioservices Revenue (US$ Million) and Gross Margin (2020-2025)
Table 193. Avid Bioservices Recent Developments
Table 194. BioVectra Corporation Information
Table 195. BioVectra Description and Major Businesses
Table 196. BioVectra Product Features and Attributes
Table 197. BioVectra Revenue (US$ Million) and Gross Margin (2020-2025)
Table 198. BioVectra Recent Developments
Table 199. CPL Corporation Information
Table 200. CPL Description and Major Businesses
Table 201. CPL Product Features and Attributes
Table 202. CPL Revenue (US$ Million) and Gross Margin (2020-2025)
Table 203. CPL Recent Developments
Table 204. Raw Materials Key Suppliers
Table 205. Distributors List
Table 206. Market Trends and Market Evolution
Table 207. Market Drivers and Opportunities
Table 208. Market Challenges, Risks, and Restraints
Table 209. Research Programs/Design for This Report
Table 210. Key Data Information from Secondary Sources
Table 211. Key Data Information from Primary Sources


List of Figures
Figure 1. Full-Service CDMO Product Picture
Figure 2. Global Full-Service CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. API CDMO Product Picture
Figure 4. FDF CDMO Product Picture
Figure 5. Packaging CDMO Product Picture
Figure 6. Clinical CDMO Product Picture
Figure 7. Global Full-Service CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Pharmaceutical Company
Figure 9. Biotechnology Company
Figure 10. Full-Service CDMO Report Years Considered
Figure 11. Global Full-Service CDMO Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 13. Global Full-Service CDMO Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Full-Service CDMO Revenue Market Share by Region (2020-2031)
Figure 15. Global Full-Service CDMO Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. API CDMO Revenue Market Share by Player in 2024
Figure 18. FDF CDMO Revenue Market Share by Player in 2024
Figure 19. Packaging CDMO Revenue Market Share by Player in 2024
Figure 20. Clinical CDMO Revenue Market Share by Player in 2024
Figure 21. Global Full-Service CDMO Revenue Market Share by Type (2020-2031)
Figure 22. Global Full-Service CDMO Revenue Market Share by Application (2020-2031)
Figure 23. North America Full-Service CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 24. North America Top 5 Players Full-Service CDMO Revenue (US$ Million) in 2024
Figure 25. North America Full-Service CDMO Revenue (US$ Million) by Type (2020 - 2031)
Figure 26. North America Full-Service CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 27. US Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 28. Canada Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 29. Mexico Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 30. Europe Full-Service CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 31. Europe Top 5 Players Full-Service CDMO Revenue (US$ Million) in 2024
Figure 32. Europe Full-Service CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 33. Europe Full-Service CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 34. Germany Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 35. France Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 36. U.K. Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 37. Italy Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 38. Russia Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Full-Service CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Top 8 Players Full-Service CDMO Revenue (US$ Million) in 2024
Figure 41. Asia-Pacific Full-Service CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 42. Asia-Pacific Full-Service CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 43. Indonesia Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 44. Japan Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 45. South Korea Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 46. Australia Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 47. India Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 48. Indonesia Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 49. Vietnam Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 50. Malaysia Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 51. Philippines Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 52. Singapore Full-Service CDMO Revenue (2020-2031) & (US$ Million)
Figure 53. Central and South America Full-Service CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Central and South America Top 5 Players Full-Service CDMO Revenue (US$ Million) in 2024
Figure 55. Central and South America Full-Service CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 56. Central and South America Full-Service CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 57. Brazil Full-Service CDMO Revenue (2020-2025) & (US$ Million)
Figure 58. Argentina Full-Service CDMO Revenue (2020-2025) & (US$ Million)
Figure 59. Middle East and Africa Full-Service CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Middle East and Africa Top 5 Players Full-Service CDMO Revenue (US$ Million) in 2024
Figure 61. South America Full-Service CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 62. Middle East and Africa Full-Service CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 63. GCC Countries Full-Service CDMO Revenue (2020-2025) & (US$ Million)
Figure 64. Israel Full-Service CDMO Revenue (2020-2025) & (US$ Million)
Figure 65. Egypt Full-Service CDMO Revenue (2020-2025) & (US$ Million)
Figure 66. South Africa Full-Service CDMO Revenue (2020-2025) & (US$ Million)
Figure 67. Full-Service CDMO Industry Chain Mapping
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed